Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on β-catenin in mouse hippocampus
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Functional interaction of β-catenin with the transcription factor LEF-1
Behrens, J., von Kries, J. P., Kühl, M., Bruhn, L., Wedlich, D., Grosschedl, R., & Birchmeier, W. (1996) · Nature · doi:10.1038/382638a0 · Cited by 2,912
β-catenin is a target for the ubiquitin–proteasome pathway
Aberle, H., Bauer, A., Stappert, J., Kispert, A., & Kemler, R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.13.3797 · Cited by 2,529
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301
Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression
Shirayama, Y., Chen, A. C.-H., Nakagawa, S., Russell, D. S., & Duman, R. S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03251.2002 · Cited by 1,654
Regulation of Cerebral Cortical Size by Control of Cell Cycle Exit in Neural Precursors
Chenn, A., & Walsh, C. A. (2002) · Science · doi:10.1126/science.1074192 · Cited by 1,431
The multifaceted roles of glycogen synthase kinase 3β in cellular signaling
Grimes, C. A., & Jope, R. S. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00011-9 · Cited by 1,423
Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321
Wnt Signaling in Oncogenesis and Embryogenesis--a Look Outside the Nucleus
Peifer, M., & Polakis, P. (2000) · Science · doi:10.1126/science.287.5458.1606 · Cited by 1,253
Cited by
Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9128-5 · Cited by 774
“Using the forced swim test, which is used to assess depressive behavior and the effects of therapeutic agents, administration of a peptide inhibitor of GSK3 rapidly induced anti-depressant-like behavioral effects [55].”
MethodLTP Inhibits LTD in the Hippocampus via Regulation of GSK3β
Peineau, S., Taghibiglou, C., Bradley, C., Wong, T. P., Liu, L., Lu, J., Lo, E., Wu, D., Saule, E., Bouschet, T., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.029 · Cited by 695
Pathogenesis of depression: Insights from human and rodent studies
Ménard, C., Hodes, G. E., & Russo, S. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.05.053 · Cited by 593
“In vivo inhibition of GSK-3Β upregulates β-catenin level in the mouse hippocampus and has antidepressant effects (Kaidanovich-Beilin et al., 2004).”
BackgroundMillan, M. J. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.11.006 · Cited by 551
GSK-3β, a pivotal kinase in Alzheimer disease
Llorens-MarÃtin, M., Jurado, J., Hernández, F., & Ãvila, J. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00046 · Cited by 451
“Several well-known non-competitive ATP binding site inhibitors of GSK3 are L803-mts (Plotkin et al., 2003; Kaidanovich-Beilin et al., 2004), TDZD-8 (Martinez et al., 2002), and VP0.”
BackgroundTherapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions
Jope, R., & Roh, M.-S. (2006) · Current Drug Targets · doi:10.2174/1389450110607011421 · Cited by 382
GSK-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder
Valvezan, A. J., & Klein, P. S. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00001 · Cited by 382
Glycogen Synthase Kinase-3: a Putative Molecular Target for Lithium Mimetic Drugs
Gould, T. D., & Manji, H. K. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300731 · Cited by 375
Yasuda, S., Liang, M.-H., Marinova, Z., Yahyavi, A., & Chuang, D.-M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002099 · Cited by 358
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
Eldar-Finkelman, H., & Martinez, A. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00032 · Cited by 354
Self-citationWNT Signaling in Cardiac and Vascular Disease
Foulquier, S., Daskalopoulos, E. P., Lluri, G., Hermans, K. C. M., Deb, A., & Blankesteijn, W. M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.013896 · Cited by 347
Prickaerts, J., Moechars, D., Cryns, K., Lenaerts, I., van Craenendonck, H., Goris, I., Daneels, G., Bouwknecht, J. A., & Steckler, T. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5216-05.2006 · Cited by 341
“Pharmacologic inhibition of GSK-3 activity was shown to produce antidepressant-like effects in rodents (Gould et al., 2004c; Kaidanovich-Beilin et al., 2004).”
BackgroundMaes, M., Fišar, Z., Medina, M., Scapagnini, G., Nowak, G., & Berk, M. (2012) · Inflammopharmacology · doi:10.1007/s10787-011-0111-7 · Cited by 325
Gould, T. D., Einat, H., Bhat, R., & Manji, H. K. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004535 · Cited by 314
Is Glycogen Synthase Kinase-3 a Central Modulator in Mood Regulation?
Li, X., & Jope, R. S. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.105 · Cited by 294
“Intracerebroventricular injection in rats of a small peptide GSK3 inhibitor, L803-mts, decreased immobility in the forced swim test (Kaidanovich-Beilin et al, 2004), suggesting that this GSK3 inhibitor has antidepressant-like actions.”
Inhibition of GSK3 by lithium, from single molecules to signaling networks
Freland, L., & Beaulieu, J.-M. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00014 · Cited by 269
Liu, R.-J., Fuchikami, M., Dwyer, J. M., Lepack, A. E., Duman, R. S., & Aghajanian, G. K. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.128 · Cited by 256
Gould, T. D., Quiroz, J. A., Singh, J., Zarate, C. A., & Manji, H. K. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001518 · Cited by 238
5-HT1A receptor-regulated signal transduction pathways in brain
Polter, A. M., & Li, X. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.03.019 · Cited by 225
Polter, A., Beurel, E., Yang, S., Garner, R., Song, L., Miller, C. A., Sweatt, J. D., McMahon, L., Bartolucci, A. A., Li, X., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.43 · Cited by 225
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
“Considerable previous evidence implicates deficient GSK-3 serine-phosphorylation in vulnerability to mood-related behavioural disturbances.([176-179]) Consequently, modulating GSK-3 by serine-phosphorylation has been suggested as an important mechanism for mood regulation.”
BackgroundLeng, Y., Liang, M.-H., Ren, M., Marinova, Z., Leeds, P., & Chuang, D.-M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5467-07.2008 · Cited by 214
“For example, treatment with a GSK-3 peptide inhibitor or heterozygous gene knock-out of GSK-3 in mice shows antidepressant-like effects in a forced swim test (Kaidanovich-Beilin et al., 2004; O’Brien et al., 2004).”
Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited
Harwood, A. J. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001618 · Cited by 209
Benedetti, F., Serretti, A., Colombo, C., Lorenzi, C., Tubazio, V., & Smeraldi, E. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.06.050 · Cited by 195
Benedetti, F., Serretti, A., Pontiggia, A., Bernasconi, A., Lorenzi, C., Colombo, C., & Smeraldi, E. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2004.11.022 · Cited by 184
Glycogen Synthase Kinase-3 in the Etiology and Treatment of Mood Disorders
Jope, R. S. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00016 · Cited by 176
“…of clear antidepressant effects in rodents of a variety of new small molecule inhibitors of GSK3 in addition to lithium (Gould et al., 2004; Kaidanovich-Beilin et al., 2004; O’Brien et al., 2004; Shapira et al., 2007; Beaulieu et al., 2008a; Silva et al., 2008), including on depressive…”
The role of zinc in neurodegenerative inflammatory pathways in depression
Szewczyk, B., Kubera, M., & Nowak, G. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.02.010 · Cited by 176
Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments
King, M. K., Pardo, M., Cheng, Y., Downey, K., Jope, R. S., & Beurel, E. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.010 · Cited by 171
Hippocampal MicroRNA-124 Enhances Chronic Stress Resilience in Mice
Higuchi, F., Uchida, S., Yamagata, H., Abe-Higuchi, N., Hobara, T., Hara, K., Kobayashi, A., Shintaku, T., Itoh, Y., Suzuki, T., et al. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0319-16.2016 · Cited by 158
GSK-3 β at the Intersection of Neuronal Plasticity and Neurodegeneration
Jaworski, T., Banach-Kasper, E., & Gralec, K. (2019) · Neural Plasticity · doi:10.1155/2019/4209475 · Cited by 159
“Furthermore, the administration of the GSK-3β peptide inhibitor, ATP competitive inhibitor, and lithium and the genetic reduction of GSK-3β in GSK-3β mice produce antidepressant behavioral effects, such as decreased immobilization time in FST, which is indicative of depressive behavior [69, 144, 145].”
BackgroundLithium: the pharmacodynamic actions of the amazing ion
Brown, K. M., & Tracy, D. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312471963 · Cited by 140
“…relevance is emerging from animal studies, which link GSK3 and manic- or depressive-like behaviours [Beaulieu et al. 2004; Gould et al. 2004; Kaidanovich-Beilin et al. 2004; O’Brien et al. 2004, Prickaerts et al. 2006; Polter et al. 2010], potentially due to lithium-induced Akt activation…”
BackgroundGriebel, G., Stemmelin, J., Lopez-Grancha, M., Boulay, D., Boquet, G., Slowinski, F., Pichat, P., Beeské, S., Tanaka, S., Mori, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-54557-5 · Cited by 97
Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits
Beurel, E., & Jope, R. S. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.129 · Cited by 92
GSK3β: a master player in depressive disorder pathogenesis and treatment responsiveness
Duda, P., Hajka, D., Wójcicka, O., Rakus, D., & Gizak, A. (2020) · Cells · doi:10.3390/cells9030727 · Cited by 84
“Intracerebroventricular injection of a novel GSK3β substrate competitive inhibitor, L803-mts, has reduced the duration of immobility in the forced swim test in mice, in comparison to control animals [73].”
BackgroundYang, X.-H., Song, S.-Q., & Xu, Y. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s150028 · Cited by 84
Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases
Beurel, E. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00018 · Cited by 82
Reverse translational strategies for developing animal models of bipolar disorder
Malkesman, O., Austin, D. R., Chen, G., & Manji, H. K. (2009) · Disease Models & Mechanisms · doi:10.1242/dmm.001628 · Cited by 70
“In addition, pharmacologic inhibition of GSK-3 activity produces antidepressant-like effects in rodents (Gould et al., 2004b; Kaidanovich-Beilin et al., 2004).”
BackgroundTsai, S.-J., Liou, Y.-J., Hong, C.-J., Yu, Y. W.-Y., & Chen, T.-J. (2008) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500486 · Cited by 66
A role for nuclear β-catenin in SNRI antidepressant-induced hippocampal cell proliferation
Mostany, R., Valdizán, E. M., & Pazos, A. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.04.012 · Cited by 47
Mathias, S. R., Knowles, E. E. M., Kent, J. W., McKay, D. R., Curran, J. E., de Almeida, M. A. A., Dyer, T. D., Göring, H. H. H., Olvera, R. L., Duggirala, R., et al. (2016) · Human Brain Mapping · doi:10.1002/hbm.23025 · Cited by 28
“Mice administered intracerebroventricularly with GSK-3 inhibitors, where GSK-3 phosphorylates b-catenin, showed antidepressant effects and concomitant increased b-catenin expression in the hippocampus [Kaidanovich-Beilin et al., 2004].”
Ni, X., Liao, Y., Li, L., Zhang, X., & Wu, Z. (2018) · Journal of Integrative Neuroscience · doi:10.3233/jin-170052 · Cited by 26
Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site
Rippin, I., Khazanov, N., Ben Joseph, S., Kudinov, T., Berent, E., Arciniegas Ruiz, S. M., Marciano, D., Levy, L., Gruzman, A., Senderowitz, H., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228709 · Cited by 25
Self-citation
Metadata
- Authors
- Kaidanovich-Beilin, O., Milman, A., Weizman, A., Pick, C. G., & Eldar-Finkelman, H.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 55
- Issue
- 8
- Pages
- 781-784
- ISSN
- 0006-3223 (ISSN-L)
- OpenAlex
- W1993796910
- Cited by
- 276
- References
- 44
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.